Compare CCLD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | STTK |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | 3650 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 275.9M |
| IPO Year | N/A | 2020 |
| Metric | CCLD | STTK |
|---|---|---|
| Price | $3.59 | $5.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.50 | ★ $7.60 |
| AVG Volume (30 Days) | 413.5K | ★ 576.6K |
| Earning Date | 01-01-0001 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $11.92 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | $32.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $0.69 |
| 52 Week High | $4.01 | $6.27 |
| Indicator | CCLD | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 81.09 | 71.91 |
| Support Level | $3.23 | $1.85 |
| Resistance Level | $3.87 | N/A |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | 0.12 | 0.12 |
| Stochastic Oscillator | 95.38 | 88.39 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.